Calamos Advisors
XGN icon

Calamos Advisors’s Exagen XGN Stock Holding History

Calamos Advisors’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-56,306
Closed -$342K – 1282
2025
Q4 		$342K Sell
56,306
-21,784
-28% -$198K ﹤0.01% 808
2025
Q3 		$858K Buy
78,090
+2,677
+4% +$23.7K ﹤0.01% 722
2025
Q2 		$526K Buy
+75,413
New +$458K ﹤0.01% 743
2021
Q4 		– Sell
-11,768
Closed -$160K – 1173
2021
Q3 		$160K Sell
11,768
-15,373
-57% -$204K ﹤0.01% 964
2021
Q2 		$407K Sell
27,141
-79,806
-75% -$1.22M ﹤0.01% 894
2021
Q1 		$1.87M Buy
+106,947
New +$1.91M 0.01% 705
2020
Q4 		– Sell
-17,474
Closed -$189K – 768
2020
Q3 		$189K Sell
17,474
-33,320
-66% -$429K ﹤0.01% 693
2020
Q2 		$631K Sell
50,794
-68,277
-57% -$924K ﹤0.01% 673
2020
Q1 		$1.9M Sell
119,071
-97,731
-45% -$1.94M 0.01% 549
2019
Q4 		$5.5M Buy
216,802
+66,825
+45% +$1.19M 0.03% 508
2019
Q3 		$2.32M Buy
+149,977
New +$2.42M 0.01% 604

Other funds holding XGN

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $179M AUM 37.68% 1-Year Est. Return

Calamos Advisors's XGN Position: Q1 2026 in Review

Calamos Advisors sold out of Exagen (XGN) in Q1 2026, closing a stake of 56,306 shares — an estimated $342K sold.

Calamos Advisors first reported a position in XGN in Q3 2019 and held it in 11 quarters. The position peaked at $5.5M in Q4 2019. 61 funds tracked by Wall St. Rank hold XGN as of Q1 2026.

  • Calamos Advisors reported no remaining Exagen position as of Q1 2026 after selling out during the quarter.
  • Calamos Advisors sold 56,306 Exagen shares in Q1 2026, an estimated $342K.
  • Calamos Advisors first reported a position in Exagen in Q3 2019 and held it in 11 quarters.
  • Calamos Advisors's Exagen position peaked at $5.5M in Q4 2019.
  • 61 funds tracked by Wall St. Rank held Exagen as of Q1 2026.

Based on Calamos Advisors's 13F filing for Q1 2026, filed 4 May 2026.